Two pneumonia vaccines from Mercedon and Pfizer are in short supply in the European market

The COVID-19 outbreak of new crown pneumonia continues to rage in Fandong, and as the seasons change, health regulators are already concerned that a new coronavirus, pneumonia and seasonal influenza could be combined, resulting in a new wave of outbreaks.
, there was already a shortage of two major pneumococcal vaccines on the EUROPEAN market, which may not bode well for the next few months of outbreak control.
' Pneumovax 23 and Pfizer's Prevnar 13 face shortages in the European market as researchers try to use two pneumococcal vaccines as a preventive measure against COVID-19, Reuters reported.
Despite the normal availability of vaccines from the United States, hospital systems are beginning to worry that COVID-19 and pneumonia patients will put double pressure on hospitals as winter approaches and a large number of European countries are forced to ration two pneumonia vaccines.
a spokeswoman for Mercer East said the "unprecedented surge in demand for vaccines" had put supplies at the two drugmakers at a high level of strain.
we have done our best, global demand for pneumonia vaccines still exceeds the availability of vaccines in some markets, " he said.
we are continuing to closely assess the situation and are working to provide as many pneumonia vaccines as possible to countries around the world.
" Pfizer spokesman said in an e-mail that Pfizer will ensure that the company is able to provide adequate and available stocks of Prevnar worldwide and further increase production to ensure that the supply of the vaccine does not cause systemic problems.
Italy, supplies of both vaccines are scarce and "in fact, there is little to be found on the market," a source told Reuters.
is understood to have approved a temporary plan for pharmacies, while Italy has also begun buying vaccines abroad.
germany, which has raised the minimum age for vaccine use in older people from 60 to 70, is trying to cope with the shortage by reducing the scope of vaccine use and limiting demand.
Germany has also signed a Pneumovax deal with Japan for this purpose, but the actual supply may not be available until January.
the European Union market is facing a shortage of vaccines for pneumonia, global health authorities are concerned that a simultaneous outbreak of the powerful COVID-19, pneumonia and seasonal flu could overwhelm the hospital system, and major pharmaceutical companies are increasing shipments of the vaccine.
O'Hara, head of Sanofi Pasteur's North America operations, said in June that the surge in third infections from COVID-19 in the United States continued, and that Sanofi planned to distribute 20 million doses of the vaccine, a significant increase from the 17 million doses supplied in 2019.
O'Hara said Sanofi would supply 80m doses of flu vaccine this year, up from 70m last year.
, a global leader in influenza prevention, supplied 52m doses last year and plans to increase supplies by about 10 per cent in the next quarter.
, the world's third-largest maker of influenza vaccines, supplied 46 million doses last year and plans to increase supplies to 50 million this year.
addition to the pneumonia vaccine, many drugmakers are working on the COVID-19 vaccine, and the fastest companies are expected to get emergency licenses in November.
at a one-day hearing on Thursday, experts at the U.S. Centers for Disease Control and Prevention (CDC) said that in the first few weeks of vaccination, medical and first responders would be prioritized for immunization, despite limited doses.
same time, in the early vaccination phase, the government will prioritize high-risk groups at risk of severe COVID-19, including people with relatively small living distances, teachers and limited access to vaccination.
, head of Warp Speed, predicted earlier this week that the COVID-19 vaccine for Moderna and Pfizer could reach all Americans by June 2021 if political factors are excluded.
source: Merck, Pfizer pneumonia vaccines running low in EU as researchers fight COVID-19: report